en sv

Press Releases

NextCell approved for trading on Nasdaq First North

NextCell Pharma AB (publ) (“NextCell” or “the Company”) announces that Nasdaq Stockholm AB today has approved their application for trading on Nasdaq Stockholm First North. The last day for trading…

Cellaviva Sverige July 6, 2020

NextCell Pharma AB’s rights issue heavily oversubscribed

The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders (the…

Cellaviva Sverige June 24, 2020

NextCell's phase II study is completed – a phase III is being prepared

NextCell Pharma AB (“NextCell”) announces that the last patient now has left ProTrans-2, meaning the phase II trial with the drug candidate ProTrans for treatment of type 1 diabetes, is…

Cellaviva Sverige June 9, 2020

NextCell Pharma AB publishes prospectus relating to the rights issue and announces the intention of change of listing to Nasdaq First North in July

The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) has prepared a prospectus (the “Prospectus”) relating to the new issue of shares with preferential rights for existing…

Cellaviva Sverige June 3, 2020

Invited to panel discussion; Post-Covid-19 world

NextCell Pharma AB (“NextCell”) has been invited to participate in the panel discussion entitled “The impact of corona virus on the global healthcare – new challenges and main problems”. Doctor…

Cellaviva Sverige May 28, 2020

The Board of Directors of NextCell Pharma AB resolves on a fully guaranteed SEK 25.1 million rights issue

NextCell Pharma AB (“NextCell” or the “Company”) announces that the Board of NextCell Pharma AB has resolved to conduct a fully guaranteed new issue of shares of approximately SEK 25.1…

Cellaviva Sverige May 15, 2020

NextCell Pharma AB publishes its interim report for September 2019 - February 2020

NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 – February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports Second quarter…

Cellaviva Sverige April 29, 2020

NextCell in discussions about patients with covid-19

NextCell Pharma AB (“NextCell”) announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with…

Cellaviva Sverige March 20, 2020

The stem cell company NextCell Pharma is preparing for a pivotal phase III trial

NextCell Pharma AB (“NextCell”) announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns…

Cellaviva Sverige March 11, 2020

The stem cell company NextCell Pharma participates as a reference laboratory in NIBSC study

NextCell Pharma AB (“NextCell”) announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference…

Cellaviva Sverige February 21, 2020

Participates in innovation projects for cell-based products

NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry…

Cellaviva Sverige February 10, 2020

NextCell to present its progress at Swiss Nordic Bio 2020

NextCell Pharma AB (“NextCell”) presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high…

Cellaviva Sverige February 4, 2020